|
TNGX Tango Therapeutics Inc 1819133 |
| Income Statement |
|
Net Income
|
2026-06-30
|
$-55,341,000.00 |
| Balance Sheet |
|
Current Assets
|
$1,031,671,000.00 |
|
Assets
|
$1,073,880,000.00 |
|
Current Liabilities
|
$20,299,000.00 |
|
Liabilities
|
$49,348,000.00 |
|
Equity
|
$1,024,532,000.00 |
|
Shares Out
|
168380091.00 |
| Cash Flow Statement |
|
Operating Cash Flow
|
$-83,226,000.00 |
|
Investing Cash Flow
|
$-436,338,000.00 |
| Market Analysis |
Market Cap
|
$3,958,615,939.41 |
|
Price
|
$23.51 |
|
BVPS
|
6.08 |
|
PB
|
3.87 |
|
EPS
|
-0.37 |
|
FCF
|
$-83,248,000.00 |
|
| Dividends |
|
Dividend Data Last Updated
|
2026-09-01 09:32:23 |
|
|
| Earnings |
|
Earnings Last Updated
|
2026-09-14 10:01:15 |
|
| Apr |
May |
Jun |
| 2026-03-05 |
-0.29 |
|
|
2026-05-13 |
-0.32 |
|
| Jul |
Aug |
Sep |
|
|
|
|
2025-08-05 |
-0.35 |
|
| Oct |
Nov |
Dec |
|
|
|
|
2025-11-04 |
0.14 |
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view TNGX documents filed with the SEC.
TNGX Filings
Clear
